HKG epiTherapeutics Limited Announces the Launch of its MetaGen Mutations Panel

Advanced Genetic Methylation Test Offers Consumers a Personalized Approach to Healthy Aging

HONG KONG, Jan. 31, 2024 /PRNewswire/ -- HKG epiTherapeutics Limited ("HKG" or "the Company"), a commercial-stage biotech company developing novel tools for the early detection of cancer and promoting healthy aging, announced today the launch of its new product, MetaGen Mutations Panel, an innovative genetic methylation test, which evaluates specific genes that offer individuals unparalleled insights into their genetic profiles and their effects on health and aging.

Developed by an esteemed team of scientists under the leadership of Prof. Moshe Szyf, a global pioneer in epigenetics, the MetaGen Mutations Panel is a simple saliva test that evaluates specific single nucleotide polymorphisms (SNPs) within five crucial genes: AHCY, COMT, MTHFR, MTR and MTRR. These genes play a key role in the body's methylation processes, influencing a wide array of biological functions – from DNA methylation and repair and detoxification – to neurotransmitter synthesis. Consumers who order the MetaGen Mutations Panel will receive a bundle that also includes HKG's proprietary epiAge test, a biological age test that utilizes a DNA age saliva testing kit to determine your actual body age, which is based on DNA methylation, and HKG's proprietary epiSmoke test to assess smoke exposure effects.

"The launch of our MetaGen Mutations Panel is a true testament to HKG's commitment to empowering individuals with detailed health insights, enabling informed decisions about nutrition, lifestyle and health management strategies," said Prof. Szyf, HKG's Founder and CEO. "Our vision at HKG is to harness the transformative power of epigenetics to improve individual health and wellness. The launch of this new product marks a significant step towards this goal, offering a holistic and scientifically grounded tool for personalized health."

The MetaGen Mutations Panel is now available for purchase online, shipped directly to customers for easy access to health insights. Upon receipt of a saliva-based DNA sample, HKG's CAP-CLIA accredited laboratory in Hong Kong processes and analyzes the sample, with results delivered directly via email. For more information, please visit the website here.

About HKG epiTherapeutics Limited
HKG epiTherapeutics Limited is a commercial-stage biotech company developing novel tools for the early detection of cancer and promoting healthy aging. Through translating its pioneering epigenetic research into innovative medical and consumer-focused tests, HKG provides valuable genetic insights that empower healthcare professionals and individuals to adopt a more personalized, proactive approach to healthcare. For more information, visit https://hkgepitherapeutics.com/. 

Media Contacts
Raquel Cona / Shana Marino
KCSA Strategic Communications
[email protected] / [email protected]

SOURCE HKG Epitherapeutics